Status:
TERMINATED
Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis
Lead Sponsor:
University of Kansas Medical Center
Collaborating Sponsors:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Conditions:
Epistaxis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Epistaxis is a common problem among people of all ages and backgrounds. However, occasionally epistaxis can be severe enough to require emergency room admission. Among the treatment options for epista...
Eligibility Criteria
Inclusion
- English speaking adults that have failed first line therapy for anterior epistaxis in the ER or the hospital
Exclusion
- Non-english speaking patients
- Patients with bleeding disorders
- Known pregnant women or women that think they may be pregnant
- Patients with a know presence of antibodies to bovine thrombin preparations
- Patients that currently have or are known to have a history of systemic skin condition or rash such as eczema or psoriasis
- Patients found to have posterior epistaxis
- Patients requiring a surrogate for medical decisions
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00814333
Start Date
December 1 2008
End Date
August 1 2011
Last Update
January 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160